At this time, FreeStyle Libre 3 is not currently eligible for Medicare reimbursement, and Medicaid eligibility may vary by state.

Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

* or ♢ Eligible patients will receive one (1) FreeStyle Libre 3 sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1 or Type 2 diabetes; it is not available for patients with gestational diabetes. Patients ages 18 and older are eligible to sign up and receive an offer for the (1) FreeStyle Libre 3 sensor. Patients ages 4-17 are eligible to receive an offer for the (1) FreeStyle Libre 3 sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Kaiser Permanente, Medicare, Medicaid or other federal or state healthcare programs, residents of Massachusetts, or US territories (other than Puerto Rico). The free (1) FreeStyle Libre 3 sensor is provided as a sample and is limited to one NDC per eligible person. The FreeStyle Libre 3 sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.

† Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore, the study data is applicable to both products.

‡ Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User’s Manual for more information.

§ The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 3 app requires registration with LibreView.

II 60-minute warm-up required when starting the sensor.

¶ Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.

# Based on a comparison of list prices of the FreeStyle Libre 3 system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any. Does not include Medicare, Medicaid, and uninsured patients.

** Based on prescription claims for commercially insured patients using the FreeStyle Libre Personal CGM systems. Does not include Medicare, Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre 3 system requires a prescription.

†† Participating pharmacies are subject to change without notice. Product availability may vary by retailer.

‡‡ Abbott uses text and short code (SMS) messaging to communicate with you and to provide general informational messages and promotional marketing messages to you on your cell phone. Message and data rates may apply. You can cancel the SMS service at any time. Just reply “STOP” to any message or text "STOP" to the short code provided. After you send the SMS message "STOP" to us, we will send you an SMS message to confirm that you have been unsubscribed. After this, you will no longer receive SMS messages from us. If you want to join again, just sign up as you did the first time, and we will start sending SMS messages to you again. If you are experiencing issues with the messaging program you can text “HELP” to the short code or reply “HELP” to any message, or you can get help directly from our toll-free number, 855-632-8658. Message frequency may vary. As the program will involve the transmission and use of your personal information, it is subject to Abbott’s Privacy Policy. Abbott may change or end the messaging program at its discretion, and content may not be available on all carriers. Abbott may add or remove carriers at our discretion and at any time without any notification. Participating carriers may include, but not be limited to: AT&T, Verizon Wireless, Sprint, T-Mobile, MetroPCS, U.S. Cellular, Alltel, Boost Mobile, Nextel, Virgin Mobile, Alaska Communications Systems (ACS), Appalachian Wireless (EKN), Bluegrass Cellular, Cellular One of East Central IL (ECIT), Cellular One of Northeast Pennsylvania, Cincinnati Bell Wireless, Cricket, Coral Wireless (Mobi PCS), COX, Cross, Element Mobile (Flat Wireless), Epic Touch (Elkhart Telephone), GCI, Golden State, Hawkeye (Chat Mobility), Hawkeye (NW Missouri), Illinois Valley Cellular, Inland Cellular, iWireless (Iowa Wireless), Keystone Wireless (Immix Wireless/PC Man), Mosaic (Consolidated or CTC Telecom), Nex-Tech Wireless, NTelos, Panhandle Communications, Pioneer, Plateau (Texas RSA 3 Ltd), Revol, RINA, Simmetry (TMP Corporation), Thumb Cellular, Union Wireless, United Wireless, Viaero Wireless, and West Central (WCC or 5 Star Wireless), and usage is subject to their respective terms of service. You can contact your wireless provider with any questions about your text or data plan. Abbott and carriers are not liable for delayed or undelivered messages. 

## NOTICE OF FINANCIAL INCENTIVE. Abbott offers the MyFreeStyle program, which provides individuals who enroll with personalized discounts, product vouchers, promotional opportunities, and/or other benefits ("Program Benefits"). Program participants opt in by signing up for the Program on this form. Abbott collects and uses your personal information, including information you voluntarily provide us above and commercial information (such as your purchase history), information we collect automatically, and information from other sources to operate the Program and related services, including to send you promotions, content, special offers, and other personalized benefits and the other uses described on this form. Based on our reasonable and good faith estimate, Abbott receives value from the Program through increased customer loyalty and sales, but we do not assign an independent monetary value to the personal information we collect in connection with the Program. Further, the precise value of your participation in the Program will vary by the Program participant depending on purchases made, which offers a participant takes advantage of, as well as other factors. Some benefits to participants may also be intangible, such as the ability to streamline ordering of products and/or payment process. In general, however, Abbott estimates in good faith that the value provided by Program Benefits to customers is equal to or greater than the value we receive from the personal information collected through the Program. Abbott incurs a variety of expenses for providing financial incentives, including administrative and technical expenses associated with maintaining the Program and costs associated with discounts on purchases. Participation in our financial incentives is voluntary. By providing your personal information when signing up for the Program, you are affirmatively opting-in to our financial incentive Program. You may unsubscribe from Program emails you receive at any time by clicking the unsubscribe link in the emails. You can also request to opt out at any time by calling (888) 332-0121 or you can submit a privacy rights request by submitting your information here: https://www.abbott.com/privacy-policy/dsar.html. Please mention the name of the Program in your request to opt-out.

References: 1. Fokkert, Marion, et al. "Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)." BMJ Open Diabetes Research and Care 7 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 2. FreeStyle Libre 3 User's Manual. 3. Bolinder, Jan, et al. "Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial." The Lancet 10057, no. 388 (2016): 2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 4. Yaron, Marianna, et al. "Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes." Diabetes Care 42, no. 7 (2019); 1178-1184. https://doi.org/10.2337/dc18-0166. 5. Alva, Shridhara, Timothy Bailey, Ronald Brazg, Erwin S. Budiman, Kristin Castorino, Mark P. Christiansen, Gregory Forlenza, Mark Kipnes, David R. Liljenquist, and Hanqing Liu. "Accuracy of a 14-day factory-calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes." Journal of Diabetes Science and Technology 16, no. 1 (2022): 70-77. https://doi.org/10.1177/1932296820958754. 6. Data on File. Abbott Diabetes Care.

ADC-63361 v3.0 12/22